Jolanta Parada-Turska

Jolanta Parada-Turska

Auto-generated profile, based on publicly available information

Jolanta Parada-Turska

Department of Rheumatology and Connective Tissue Diseases, Medical University of Lublin, 20-090 Lublin, Poland

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

31 January 2008 in Amino Acids
Verified
Journal Article
Closed access
PDF file
DKD. Kuc
D. Kuc
WZW. Zgrajka
W. Zgrajka
JPJ. Parada-Turska
J. Parada-Turska
TUTeresa Urbanik-Sypniewska
Teresa Urbanik-Sypniewska
WTWaldemar Turski
Waldemar Turski

23 May 2003 in Neuropsychopharmacology
Verified
Journal Article
Closed access
JŁJarogniew J. Łuszczki
Jarogniew J. Łuszczki
MSMariusz Swiader
Mariusz Swiader
JPJolanta Parada-Turska
Jolanta Parada-Turska
SCStanisław J Czuczwar
Stanisław J Czuczwar

Verified
Journal Article
Open access
PDF file
Artur WnorowskiArtur Wnorowski
Artur Wnorowski
SWSylwia Wnorowska
Sylwia Wnorowska
Jacek KurzepaJacek Kurzepa
Jacek Kurzepa
JPJolanta Parada-Turska
Jolanta Parada-Turska
A meta-analysis of publicly available transcriptomic datasets was performed to identify metabolic pathways profoundly implicated in the progression and treatment of inflammatory bowel disease (IBD). The analysis revealed that genes involved in tryptophan (Trp) metabolism are upregulated in Crohn’s disease (CD) and ulcerative colitis (UC) and return to baseline after successful treatment with infliximab. Microarray and mRNAseq profiles from multiple experiments confirmed that enzymes responsible for Trp degradation via the kynurenine pathway (IDO1, KYNU, IL4I1, KMO, and TDO2), receptor of Trp metabolites (HCAR3), and enzymes catalyzing NAD+ turnover (NAMPT, NNMT, PARP9, CD38) were synchronously coregulated in IBD, but not in intestinal malignancies. The modeling of Trp metabolite fluxes in IBD indicated that changes in gene expression shifted intestinal Trp metabolism from the synthesis of 5-hydroxytryptamine (5HT, serotonin) towards the kynurenine pathway. Based on pathway modeling, this manifested in a decline in mucosal Trp and elevated kynurenine (Kyn) levels, and fueled the production of downstream metabolites, including quinolinate, a substrate for de novo NAD+ synthesis. Interestingly, IBD-dependent alterations in Trp metabolites were normalized in infliximab responders, but not in non-responders. Transcriptomic reconstruction of the NAD+ pathway revealed an increased salvage biosynthesis and utilization of NAD+ in IBD, which normalized in patients successfully treated with infliximab. Treatment-related changes in NAD+ levels correlated with shifts in nicotinamide N-methyltransferase (NNMT) expression. This enzyme helps to maintain a high level of NAD+-dependent proinflammatory signaling by removing excess inhibitory nicotinamide (Nam) from the system. Our analysis highlights the prevalent deregulation of kynurenine and NAD+ biosynthetic pathways in IBD and gives new impetus for conducting an in-depth examination of uncovered phenomena in clinical studies.

1 May 2016 in Journal of Food Composition and Analysis
Verified
Journal Article
Closed access
MTMichal P. Turski
Michal P. Turski
SCStanisław Chwil
Stanisław Chwil
MTMonika Katarzyna Turska-Kozłowska
Monika Katarzyna Turska-Kozłowska
MCMirosława Chwil
Mirosława Chwil
TKTomasz Kocki
Tomasz Kocki
JPJolanta Parada-Turska
Jolanta Parada-Turska

Verified
Journal Article
Open access
PDF file
KGKinga Gawel
Kinga Gawel
Wirginia Kukula-KochWirginia Kukula-Koch
Wirginia Kukula-Koch
NBNancy Saana Banono
Nancy Saana Banono
DNDorota Nieoczym
Dorota Nieoczym
KTKatarzyna Targowska-Duda
Katarzyna Targowska-Duda
CECamila Esguerra
Camila Esguerra
Zingiber officinale is one of the most frequently used medicinal herbs in Asia. Using rodent seizure models, it was previously shown that Zingiber officinale hydroethanolic extract exerts antiseizure activity, but the active constituents responsible for this effect have not been determined. In this paper, we demonstrated that Zingiber officinale methanolic extract exerts anticonvulsant activity in the pentylenetetrazole (PTZ)-induced hyperlocomotion assay in larval zebrafish. Next, we isolated 6-gingerol (6-GIN)—a major constituent of Zingiber officinale rhizoma. We observed that 6-GIN exerted potent dose-dependent anticonvulsant activity in the PTZ-induced hyperlocomotion seizure assay in zebrafish, which was confirmed electroencephalographically. To obtain further insight into the molecular mechanisms of 6-GIN antiseizure activity, we assessed the concentration of two neurotransmitters in zebrafish, i.e., inhibitory γ-aminobutyric acid (GABA) and excitatory glutamic acid (GLU), and their ratio after exposure to acute PTZ dose. Here, 6-GIN decreased GLU level and reduced the GLU/GABA ratio in PTZ-treated fish compared with only PTZ-bathed fish. This activity was associated with the decrease in grin2b, but not gabra1a, grin1a, gria1a, gria2a, and gria3b expression in PTZ-treated fish. Molecular docking to the human NR2B-containing N-methyl-D-aspartate (NMDA) receptor suggests that 6-GIN might act as an inhibitor and interact with the amino terminal domain, the glutamate-binding site, as well as within the ion channel of the NR2B-containing NMDA receptor. In summary, our study reveals, for the first time, the anticonvulsant activity of 6-GIN. We suggest that this effect might at least be partially mediated by restoring the balance between GABA and GLU in the epileptic brain; however, more studies are needed to prove our hypothesis.